However, in contrast to both published studies, which were done using conventional mice, this current work has demonstrated in a human immune system model that a PGLA-based NP vaccine which encapsulated a tumor antigen and α-GalCer and decorated by anti-CLEC9A can actually engage both populations of human iNKT cells and human CD141+ DCs in vivo. The gene discussed is CLEC9A; the disease is neoplasm.